ENRICHED EPIDERMAL LANGERHANS CELLS ARE POTENT ANTIGEN-PRESENTING CELLS FOR T-CELLS

被引:57
作者
BJERCKE, S [1 ]
ELGO, J [1 ]
BRAATHEN, L [1 ]
THORSBY, E [1 ]
机构
[1] NATL HOSP NORWAY, DEPT DERMATOL, OSLO, NORWAY
关键词
D O I
10.1111/1523-1747.ep12340417
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Human epidermis was separated from dermis by means of a suction blister device, and was dissociated with trypsin. The epidermal cell (Ec) suspensions contained 2-6% Langerhans cells (Lc). Using a new rosette technique for enrichment of Lc, suspensions were obtained that contained 50-92% viable Lc. Ec, enriched Lc, or peripheral blood monocytes (Mo) were cocultured with or without antigens (Candida albicans, herpes simplex virus) and autologous T lymphocytes from sensitized donors. Strong proliferative T-cell responses were obtained provided Ec, enriched Lc, or Mo were also present. Furthermore, Lc were more effective than similar numbers of Mo in inducing T-cell responses to the antigens tested, and Lc did not require the presence of significant numbers of keratinocytes to exert this function.
引用
收藏
页码:286 / 289
页数:4
相关论文
共 19 条
[1]  
BJERCKE S, SCAND J IMMUNOL
[2]  
BJERCKE S, ACTA OBSTET GYNECOL
[3]   STUDIES ON HUMAN EPIDERMAL LANGERHANS CELLS .3. INDUCTION OF LYMPHOCYTE-T RESPONSE TO NICKEL SULFATE IN SENSITIZED INDIVIDUALS [J].
BRAATHEN, LR .
BRITISH JOURNAL OF DERMATOLOGY, 1980, 103 (05) :517-526
[4]  
BRAATHEN LR, 1980, ACTA DERM-VENEREOL, V60, P381
[5]   STUDIES ON HUMAN EPIDERMAL LANGERHANS CELLS .1. ALLO-ACTIVATING AND ANTIGEN-PRESENTING CAPACITY [J].
BRAATHEN, LR ;
THORSBY, E .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1980, 11 (04) :401-408
[6]   HUMAN EPIDERMAL LANGERHANS CELLS ARE MORE POTENT THAN BLOOD MONOCYTES IN INDUCING SOME ANTIGEN-SPECIFIC T-CELL RESPONSES [J].
BRAATHEN, LR ;
THORSBY, E .
BRITISH JOURNAL OF DERMATOLOGY, 1983, 108 (02) :139-146
[8]   CHEMICAL PROPERTIES OF HUMAN IA ANTIGENS [J].
KLARESKOG, L ;
SANDBERGTRAGARDH, L ;
RASK, L ;
LINDBLOM, JB ;
CURMAN, B ;
PETERSON, PA .
NATURE, 1977, 265 (5591) :248-251
[9]  
KUNTZCROW M, 1982, CLIN EXP IMMUNOL, V49, P338
[10]  
LUGER TA, 1981, J IMMUNOL, V127, P1493